- Home
- FFIN vs MIRM Comparison
FFIN vs MIRM Comparison
Compare FFIN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FFIN | MIRM |
|---|---|---|
| Founded | 1890 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 5.7B |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FFIN | MIRM |
|---|---|---|
| Price | $30.97 | $95.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $36.50 | ★ $115.33 |
| AVG Volume (30 Days) | 591.4K | ★ 788.7K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | 13.46 | ★ 74.59 |
| EPS | ★ 1.77 | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $17.16 | $26.22 |
| Revenue Next Year | $6.61 | $22.04 |
| P/E Ratio | $17.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.12 | $38.22 |
| 52 Week High | $38.74 | $109.28 |
Technical Indicators
Market Signals| Indicator | FFIN | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 54.91 | 52.36 |
| Support Level | $29.81 | $85.35 |
| Resistance Level | $31.74 | $98.03 |
| Average True Range (ATR) | 0.70 | 3.62 |
| MACD | 0.21 | 0.44 |
| Stochastic Oscillator | 71.68 | 67.06 |
Price Performance
Historical ComparisonAbout FFIN First Financial Bankshares Inc.
First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.